sionnatx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $331.32MM
Sionna Therapeutics is a life science company that aims to develop treatments for cystic fibrosis. The company works to research drug treatments for the disorder striving to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is essential for the regulation of salt and water balance in the body. Sionna Therapeutics was founded by Greg Hurlbut and Mark Munson in 2019 and is headquartered in Boston, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/06/2024 | Series C | $181.86MM | $xx.xx | $523.7MM | Atlas Venture, Cystic Fibrosis Foundation, Enavate Sciences, Orbimed, Perceptive Advisors, Qatar Investment Authority, Ra Capital, Tpg, T. Rowe Price, Viking Global Investors | |
Price per Share
$xx.xx
Shares Outstanding
18,628,970
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Cystic Fibrosis Foundation, Enavate Sciences, Orbimed, Perceptive Advisors, Qatar Investment Authority, Ra Capital, Tpg, T. Rowe Price, Viking Global Investors
|
||||||
04/19/2022 | Series B | $111MM | $xx.xx | $342.3MM | Atlas Venture, Cystic Fibrosis Foundation, Orbimed, Qatar Investment Authority, Ra Capital, Tpg, T. Rowe Price Associates | |
Price per Share
$xx.xx
Shares Outstanding
11,370,621
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Cystic Fibrosis Foundation, Orbimed, Qatar Investment Authority, Ra Capital, Tpg, T. Rowe Price Associates
|
||||||
06/30/2021 | Series A | $25.26MM | $xx.xx | $85.64MM | Atlas Venture, Cystic Fibrosis Foundation, Ra Capital, Tpg | |
Price per Share
$xx.xx
Shares Outstanding
5,704,161
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Cystic Fibrosis Foundation, Ra Capital, Tpg
|
||||||
06/30/2020 | Series Seed | $13.2MM | $xx.xx | $33MM | Atlas Venture, Cystic Fibrosis Foundation, Ra Capital, Tpg | |
Price per Share
$xx.xx
Shares Outstanding
3,963,963
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Atlas Venture, Cystic Fibrosis Foundation, Ra Capital, Tpg
|